Jay Brammer
Chairman of the Board
Jay Brammer is Chairman of the Board at Enterin. During his 40 year business career, Mr. Brammer has been an executive, board member and/or investor across numerous companies in various industries. Concurrently, Mr. Brammer serves as Chairman & Chief Investment Officer at Indie Asset Partners, an investment advisory firm providing alternative investment options to private clients. Prior to co-founding Indie Asset Partners, Mr. Brammer established a number of mutual funds and successfully managed multiple real estate businesses. Mr. Brammer graduated with a degree in business administration from the Indiana University.
Richard Larson, MD, PhD
Chief Executive Officer, Chief Medical Officer, and Board Member
Richard S. Larson MD, PhD has 35+ years experience in bioscience and healthcare industries. He is a physician-scientist, inventor, professor, health care leader, and entrepreneur. Dr. Larson founded and served as the director of the Clinical and Translational Science Center in New Mexico for 17 years, an organization that runs 60-250 clinical trials annually.
Dr. Larson is also an accomplished inventor and entrepreneur. His scientific achievements include more than 100 peer-reviewed publications and over 40 patents. Several patents served as the basis for new biotechnology companies in the areas of drug development, radioimaging, and in vitro diagnostics. His inventions have been recognized with the Chief Scientist Award for Excellence from the Defense Intelligence Agency and a Top 100 Technology Award from R&D Magazine. He is an honorary commander at Kirkland Air Force base.
Dr. Larson helped launch, lead, and govern TriCore Reference Laboratories, which has grown into one of New Mexico’s 9th largest businesses. In addition, having served as Executive Vice Chancellor and Vice President for Research of a $2.4 billion health care entity for more than 10 years, he has overseen a broad array of activities and programs in education, research, community outreach and clinical care. He also serves on the board of directors of Triopsy, Inc, a company developing devices and AI to improve biopsy techniques and the diagnosis of prostate cancer.
Dr. Larson received both his M.D. and Ph.D. from Harvard University. He completed his residency at Washington University in St. Louis and his fellowship training at Vanderbilt University.
Mark Finn
Board Member
Mark Finn has 49 years of investment experience. In 1975, Mark joined the predecessor to the Vantage Consulting Group as an outside consultant and was elected its Chairman and Chief Executive Officer in 1986, a capacity in which he continues to serve today. Since 1990, Mr. Finn has also served as an Independent Trustee on a number of independent open end funds sponsored by Legg Mason (previously CitiFunds).
Mr. Finn currently serves on the Board and Chairs the Finance Committee of Cibus Global, a leading agricultural biotechnology firm focused on advanced non-transgenic trait development. He also serves on the Advisory Board of Auven Therapeutics, a private equity life sciences company with an emphasis on cancer. He joined the Board of Directors at Enterin Inc. in 2017.
He has taught investments at the University of Virginia’s Colgate Darden Graduate Business School and is currently on the adjunct faculty at the Mason School of Business at the College of William & Mary, where he received his MBA. Mr. Finn also serves as the Managing Member of New Ventures I, LLC, New Ventures Select, LLC and New Ventures III.
Richard D. Propper, MD
Board Member
Dr. Propper is an experienced venture capitalist, merchant banker and financial strategist. He received a BSc from McGill University and a MD from Stanford University. Dr. Propper worked as a Research Fellow in Pediatrics at Harvard Medical School. He was also a Fellow in Medicine at the Children’s Hospital Medical Center, Fellow in Pediatric Oncology at the Dana Farber Cancer Center, and Assistant Professor in Pediatrics at Harvard Medical School. He has published over 40 papers and three textbook chapters, and is renowned for his clinical research in thalassemia major.
In 1984, Dr. Propper found Montgomery Medical Ventures, the largest seed-stage medical venture capital firm in the country at that time, with $135M in capital. In 1993, he founded the International Medical Development Corporation to pursue healthcare ventures worldwide. In 1998, he co-founded Medibuy.com., the largest Internet-based medical procurement company in the US. In 2001, Dr. Propper founded Chardan Ventures, the predecessor to Chardan Capital, LLC, a financial strategic consulting firm building business between Chinese and US companies
In 2003, he raised his first SPAC, Chardan China Acquisition Corporation, which eventually merged with Origin Agritech, and is currently a NASDAQ-listed company (SEED). In 2005, he raised two more SPACs, one of which became NASDAQ-listed HollySys (HOLI).
Dr. Propper currently serves on the Boards of FreeLinc Technologies, Inc. and HyEdge, Inc. He joined the Board of Directors at Enterin in 2016.
Don Munoz
Board Member
Don Munoz currently serves as Chief Financial Officer of NuCana plc, a Nasdaq-listed biotechnology company focused on significantly improving treatment outcomes for patients with cancer. Prior to joining NuCana in 2015, Don served as Group Chief Financial Officer of NOXXON Pharma. He has an extensive financial background with approximately 20 years as a healthcare investment banker at Alex. Brown & Sons, Deutsche Bank, Leerink Partners and Cowen. Don has completed over 100 financing and merger and acquisition transactions with an aggregate value of more than $30 billion. He received an MBA in Finance and Accounting from Columbia Business School and an AB in Psychology from Dartmouth College.
Roger Mills, MD
Board Member
Dr. Mills is a highly accomplished and well-respected drug development expert and has held numerous senior level positions during his illustrious career ushering several blockbuster drugs through FDA approval. Most recently, Dr. Mills served as Chief Medical Officer for Acadia Pharmaceuticals where he led a highly successful Ph III program in Parkinson’s Disease Psychosis. This led to the approval of the first compound for the treatment of Parkinson’s Disease related Psychosis. Prior to joining Acadia Dr. Mills served as Vice President, Pfizer Global Research and Development, where he was responsible for clinical development across a broad portfolio of therapeutic areas. Earlier in his career Dr. Mills held senior positions within Clinical Development at Gilead Sciences and Abbott Laboratories.
Dr. Mills is a Visiting Professor at the Centre for Age Related Diseases, Inst of Psychiatry, Psychology, and Neuroscience, King’s College London. He also serves as Professor of Medical Research in Practice at the University of Exeter Medical School, Exeter, UK. Additionally, he is Acting Chief Medical Officer and a member of the Board of Directors of Addex Theraputics. He received his medical degree from Imperial College, Charing Cross Hospital Medical School, London.
Barry Miller
Board Member
Barry is an entrepreneurial-oriented executive with deep experience building new enterprises within large companies as well as independent start-up companies, and he is the President of Voloridge Investment Management, LLC, a multi-strategy, quantitative hedge fund in Jupiter, Florida.
Prior to joining Voloridge Investment Management, he co-founded and served as the CEO of a business-to-business focused Finance and Insurance company. This company was successfully sold to a private equity company after achieving many years of double-digit growth in sales and EBITA.
After gaining valuable experience as an entrepreneur and chief executive officer, business development executive, financial analyst, and asset manager, Barry’s ambition led him to join and invest in the Voloridge team. He is responsible for many facets of the company’s operations including trading, back-office operations, compliance, sales and marketing, vendor relationships, and strategic planning.
Barry graduated with honors, as the finance department’s standard bearer, from The University of Central Florida with a BS in Finance. In 2022, he had the honor of being inducted into the UCF College of Business Hall of Fame.
